Brendon M. Stiles

Oct 3, 2024 | onclive.com | Sandip Patel |Brendon M. Stiles

CommentaryPodcastOctober 3, 2024Author(s):,Fact checked by:,Drs Patel and Stiles discuss the significance of the FDA approval of perioperative durvalumab for patients with resectable non–small cell lung cancer. Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care.

Aug 12, 2024 | onclive.com | Brendon M. Stiles

CommentaryVideoAugust 12, 2024Author(s):Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer. Brendon M.

Aug 3, 2023 | onclive.com | Brendon M. Stiles

Brendon Stiles, MD, chief, Divisions of Thoracic Surgery and Surgical Oncology, professor, cardiothoracic surgery, Department of Cardiothoracic & Vascular Surgery, Montefiore-Einstein, associate director, Surgical Oncology, Montefiore Einstein Cancer Center, discusses scenarios in which to refer patients with non–small cell lung cancer (NSCLC) to thoracic surgeons at specialized centers of care. Determining whether to send a patient to see a thoracic surgeon is a complex decision, Stiles begins.